logo
  

Quanta Services Boosts FY19 Outlook - Quick Facts

While reporting financial results for the first quarter, Quanta Services, Inc. (PWR) on Thursday raised its full year 2019 outlook for adjusted earnings and revenues, as a result of solid first quarter results and increased visibility for electric power services.

For fiscal 2019, the company now projects earnings in a range of $2.86 to $3.32 per share, adjusted earnings in a range of $3.40 to $3.86 per share, and revenues between $11.2 billion and $11.6 billion.

Previously, the company now expected earnings in the range of $2.76 to $3.21 per share, adjusted earnings in the range of $3.30 to $3.75 per share, and revenues between $10.8 billion and $11.2 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.47 per share on revenues of $11.04 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, net income soared to $120.5 million or $0.82 per share from $37.6 million or $0.24 per share in the prior-year quarter. Adjusted earnings were $0.96 per share, compared to last year's $0.39 per share. Revenues increased to $2.81 billion from last year's $2.42 billion.

Analysts expected quarterly earnings of $0.83 per share on sales of $2.64 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning. Science and technology firm Danaher Corp. (DHR) announced Thursday that it has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance... Biopharmaceutical company Kite Pharma, a part of Gilead Sciences, Inc. (GILD), and biotechnology company Shoreline Biosciences, Inc. announced Thursday a strategic partnership to develop novel cell therapies across a variety of cancer targets. The partnership follows Kite's investment in Shoreline's...
RELATED NEWS
Follow RTT